# The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)

> **NCT01997268** · PHASE3 · WITHDRAWN · sponsor: **Sancilio and Company, Inc.**

## Conditions studied

- Severe Hypertriglyceridemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** SC401B 2 capsules
- **DRUG:** SC401B 4 capsules
- **DRUG:** SC401B 6 capsules

## Key facts

- **NCT ID:** NCT01997268
- **Lead sponsor:** Sancilio and Company, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** 2014-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never initiated. IND placed on Hold
- **Last updated:** 2016-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01997268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01997268, "The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01997268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*